Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme class drugs

2 results

Elfabrio (pegunigalsidase alfa)

(pegunigalsidase alfa)
Chiesi USA, Inc.
Usage: ELFABRIO is indicated for the treatment of adults with confirmed Fabry disease, a genetic disorder that affects various bodily systems due to a deficiency in the enzyme alpha-galactosidase A.
Genzyme Corporation
Usage: FABRAZYME® is indicated for treating adult and pediatric patients aged 2 years and older with confirmed Fabry disease.